{"id":858961,"date":"2025-06-10T08:42:20","date_gmt":"2025-06-10T12:42:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"modified":"2025-06-10T08:42:20","modified_gmt":"2025-06-10T12:42:20","slug":"gain-therapeutics-to-participate-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","title":{"rendered":"Gain Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BETHESDA, Md., June  10, 2025  (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>H.C. Wainwright 6<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Neuro Perspectives Hybrid Conference <\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:8pt\">\n              <strong>Tuesday, June 17, at 7:00 a.m. EST: <\/strong>Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>BIO 2025 <\/strong><\/p>\n<ul type=\"circle\">\n<li style=\"margin-bottom:8pt\">\n              <strong>Wednesday, June 18, at 1:45 p.m. EST: <\/strong>Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition Center.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>Registered attendees can request one-on-one meetings with Gain management via your H.C. Wainwright banking representative or the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0e3qfopkJGBKD3bh1yg1RqCNP3XWmv6x3FByXkLLjpVXfFWxVtoVdOAcCVUr1RxTXDj4tZOkTSZjkdlWkZa_W5BKvLuy8N7MMSpnxleDu6BDAY6-iy8xRFn6nR6UISrFMKtNHtV82bNTtHRfEhhodugyL41CqcqDe8HIiAnh4QHMswoGlRhX_Efy2q-YPdUvY2YZT3fFCaJuTqu-h3cqKMuv8ottPd-38M8VwbMdIOtLXIjUsewuUoGInwW_H63RfWLD__iCTC4sUHAsIJTLsBXhiUhnpyPUEPbbE4g0Y4CY7gOn_Tr1iG-8URTdjJ6S1wDQ89qDRSVWytD32fbi_ICHIoW79AAl-WWjCbvycLR7W-9rahqP7lxtsZ1DCMnY0xrsV-gZs51dB9OheAr8KdRJVLtZ6YQLjxMDtJMKi6QUlaToztLUNTqYSi5raPpYXHA3O6NWxJgc0hQvyxC--fTn4yo3FenjUWUTCgGRISHmpWOAbDxA2S-cD4bnh-0EJFXXmJRDf0Uno7jF9ALAsuvb0nkE6bavDMp7Xg0okidG38ZtK32tLkwL0_ohozHvJGxJUAF7tGRCwU5QgBEp-HJ4uRO3G622rBSJbH7l0XDrqekffw8VRboQ5PqgfVOnlq0y1UMEWgmzGgtxW-GuoHUlsjmJh8uQpkUQ3-oClRY0EF_495lxVgfW9qgt6xuVolz_H5M-dKCxAqiqu7rqNhu6IY4LCSwTGkhzypnWrwdf7helVjMUl3KwLCtJCQZPNbWHJ912MTRdjvFlEL3mH_ubEeIN77J3I1XD0xIHSTJa366FrbomDY3iwKAjNcsFy_taNKlqy4pr9yBuEO-QfPXQRWX8GmxfvJlJ1kX__tsUuDaSZOU2o230KkQRsOajUzIu7_pMXUadh7IkHh0q9WHLcnSm0uA3IMM74gxDYxXxyFSKzwmn0VeAh1cdnfm61hvIl545vyzX1VUH27K0-756MI96XccxhIfG6lfMCSTbuYPBJYLbm0kQWJpeYzdhapLLd7-O3nLpjukG_feYUQ==\" rel=\"nofollow\" target=\"_blank\">BIO conference scheduling platform<\/a>, respectively.<\/p>\n<p>If you are unable to attend the conferences and would like to schedule a meeting with Gain management, please contact <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CHo-6CEWOwsf8T84jYTU-M6CxlZoiAT2d4Mmz7gyYcHR1FJtSd9jo3SrQtZe3eCIRiqycv2YCQA0ojeRwniyGOutgyOhJMc5EzoJUNF0EhQ=\" rel=\"nofollow\" target=\"_blank\">ir@gaintherapeutics.com<\/a><\/p>\n<p>\n        <strong>About Gain Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain\u2019s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson\u2019s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher\u2019s disease, dementia with Lewy bodies, and Alzheimer\u2019s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.<\/p>\n<p>Gain\u2019s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan\u2122 platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This release contains \u201cforward-looking statements\u201d made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d or similar expressions. These forward-looking statements reflect management\u2019s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company\u2019s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company\u2019s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company\u2019s business in general, please refer to the Company\u2019s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Gain Therapeutics, Inc.\u00a0<br \/>Apaar Jammu\u00a0<br \/>Manager, Investor Relations and Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WUN6R9cLFVRBDcAfeWcUTvkis4o3h-gYB_QiOACjm4u4q4-Hf-CvL2pnyEqhjtjMUJwK8F1kl76SY4H4weQToZeGcYKAE6Lx4XHdmJVdR5YsWVSS3Cvr8Issi32UtvFJTz7366ujxK_OFLWTmjkpBvKYuxSFfn2Tgp4WP-2cDE6BVEY0zQrpMSc3D1eerAeprgT30eVoo3q34DYoVqmEpaWWrKfKORsJDr5jmzr5bZXaJDddzDkpWoQf9m0zIx6jd3Y5Nq9xrjP1JjEGfvy3YCDjpArAR3-yoNS6HgKcAprIINnFFo3I2dr_lEsQXhyisMwlslq3w-k18j8BvKtaDzDXfKsCrpQosaYUbo2l5lFAAR3gb81YkVYe3_D8Mc05Y4k1m_exTVFgUYq3XfNibPAPoOG__yQFwsPyfx6gawM7b397jr6eHi3_MNFGjHvF3EGU88GWPLDtGR9ec-llLhu1x6l9mc9bEuKasFWR6YiGVODkEerbK0_Kf-50mXTtdA5cavt7ZUY4dSyUWhrfcaBJ_vG78PT6CNl5ThYO-glFCazdrS_MeZDaNskk-VhGV51qbWesVOqCzzYxsSix7vjaVic7VdYmCDDlI9zHosTdgMvGLyuObWheuPCM-hjAnmG4dUifNHGk_-OY4i6XH5rRkdQeDHSJvfH2RAMZEk7ooXeh8OJk0h5-DD3D2i1Qkd8CRm5eTUcML14y90bkbLdnRUfWcQ-E7fyVnEFz7cnvjNbjPs-cseHtacf_3XrdpFX0btbh7fFm7YVvTpN0eeGpL4zv8H8l2YROPF2rBfv7VHw7qZDYYIJT1Rw7YY_zKGuBHsdoJcVrRzlpNqzbVw==\" rel=\"nofollow\" target=\"_blank\">ajammu@gaintherapeutics.com<\/a><\/p>\n<p>LifeSci Advisors LLC<br \/>Chuck Padala<br \/>Managing Director<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IG1kmY3WnJ2xLqOuXeBNBNryWMyVoITDCcZG9GaMaRfwmBSGxBwNX0tRC8UiTF8C5IEXUdMiqdgCSDXfzwNc7IWX43IdGbmJJHiFSlqfdyAoXedxLElA9gLVh3RtIuFswWjdBXoZZXUzuFYAyQCdTwYxy4964z7sAs-zES0jwxSdkDVrpZ4mxiYxbnodx8nTV63NO7TutFvsyCb3kd0lQOaVtAxHN0Z82a_FwVEhE2_QIUoF4EMX4BL_HTPJNtEPRZly7GqMqC6xkkqGGp0QVXZvrWeGY4gIX2rk6mlwIlCAWBqb1kRytSTr-W8Le4JZPWZq_Qr3F76fknzUXGkeQbd2jkZil0f8tiH_jtz0nvtjnrf2NCU1e6A-MCTdmmZwS7vHxvICkWnIslbszYvg10M3zTLusyYozaQFBswYFqqyuqbOkCpMwUY2s9mN3oJIz1qgyVX8vCPzumRlQybi2yJSSLJbA8vASbshXtciGshoHne5QKWzVcwuOv_rfSe8ZCL96K8cIb5ebIUc7lQM1JIfmJ3hIRXdqXS2y_VAyagxzIFO95ct-SMwQUS6-rW31Mk5XReoDeoFfHHwtlENjAi7gzjfhuSdaybaGFM6eD2Pjx-KU9-c33M2dw6Ozet3R41TKV9fQQqbkgNHgP2_nC8cGH6Kz4zGAU7LNxbGj0dWgLLy5du1bf8wYUchnUd6lV319P3p6cMg-1ChXahiMOblITDPsg4WLQn5TTxFs9LZf8_cxHH_96aPf_ImsCzwd0nI-BmGF9jEoQOlE1a3Zh4FH1q6gxFyWZCtlMwgBilN_FgsGwaoi7yz-jBgSpoSFfV-c6rIhHnLSe58FMzxzw==\" rel=\"nofollow\" target=\"_blank\">chuck@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Russo Partners LLC <br \/>Nic Johnson and Elio Ambrosio<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=v5GCvlCgFpHMabE1npETsD0GIhmRuDGiXqfakD1NIahMwGHTLeDP3SmJn7EQQseio51YnG1WdNXzp-IB2Uotq3GFj6J_5hNpB7gXwc98ac4ikFLz_quvfTrKSBY0evnw2OsxsEfxmXY1LKusYiMiig==\" rel=\"nofollow\" target=\"_blank\">nic.johnson@russopartnersllc.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2xT9lsiw4Aztf4NgvVwHTGbDkXRwG0alUMQVwvdFSlmMd1aMSnKwhkGB_WIOsoSyed8ZeuQXVhtDB5ezzL7DahFaBw9lw1q_g06B0VD-pdFil2qSSHUYXT5dlizBn_U_g2wp6I8h6uFl588VAqRSFA==\" rel=\"nofollow\" target=\"_blank\">elio.ambrosio@russopartnersllc.com<\/a><br \/>(760) 846-9256<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWNmNTRlNmEtN2RiYy00N2JlLTg1MjktYjExNzExYTI1NWNkLTEyMjA1ODMtMjAyNS0wNi0xMC1lbg==\/tiny\/Gain-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6 th Annual Neuro Perspectives Hybrid Conference Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D. BIO 2025 Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition Center. Registered attendees can request one-on-one meetings with Gain management via your H.C. Wainwright &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Gain Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-858961","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6 th Annual Neuro Perspectives Hybrid Conference Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D. BIO 2025 Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition Center. Registered attendees can request one-on-one meetings with Gain management via your H.C. Wainwright &hellip; Continue reading &quot;Gain Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T12:42:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Gain Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2025-06-10T12:42:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":638,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\",\"name\":\"Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\",\"datePublished\":\"2025-06-10T12:42:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gain Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) &#8212; Gain Therapeutics, Inc. (Nasdaq: GANX) (\u201cGain\u201d, or the \u201cCompany\u201d), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6 th Annual Neuro Perspectives Hybrid Conference Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D. BIO 2025 Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition Center. Registered attendees can request one-on-one meetings with Gain management via your H.C. Wainwright &hellip; Continue reading \"Gain Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T12:42:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Gain Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2025-06-10T12:42:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"},"wordCount":638,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/","name":"Gain Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=","datePublished":"2025-06-10T12:42:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ2NTc5MCM2OTgyODYyIzIyMDkwMzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gain-therapeutics-to-participate-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Gain Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=858961"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/858961\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=858961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=858961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=858961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}